Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens

Virology

Volumn 367, Issue 1, 2007, Pages 175-186

  Seaman, Michael S ^a   LeBlanc, Daniel F ^a   Grandpre, Lauren E ^a   Bartman, Melissa T ^a   Montefiori, David C ^b   Letvin, Norman L ^a,c   Mascola, John R ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Envelope glycoprotein; HIV vaccine; Neutralizing antibody; Rhesus monkey; SHIV 89.6P

Indexed keywords

DNA VACCINE; ENV ANTIGEN; GLYCOPROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VIRUS INFECTION; VIRUS ISOLATION;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; IMMUNIZATION, SECONDARY; MACACA MULATTA; NEUTRALIZATION TESTS; RECOMBINATION, GENETIC; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34548695901     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.05.024     Document Type: Article

References (43)

1. Beddows S., Lister S., Cheingsong R., Bruck C., and Weber J. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J. Virol. 73 2 (1999) 1740-1745
2. Belshe R.B., Gorse G.J., Mulligan M.J., Evans T.G., Keefer M.C., Excler J.L., Duliege A.M., Tartaglia J., Cox W.I., McNamara J., Hwang K.L., Bradney A., Montefiori D., and Weinhold K.J. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 12 18 (1998) 2407-2415
3. Buckner C., Gines L.G., Saunders C.J., Vojtech L., Srivastava I., Gettie A., Bohm R., Blanchard J., Barnett S.W., Safrit J.T., and Stamatatos L. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 320 1 (2004) 167-180
4. Bures R., Gaitan A., Zhu T., Graziosi C., McGrath K.M., Tartaglia J., Caudrelier P., El Habib R., Klein M., Lazzarin A., Stablein D.M., Deers M., Corey L., Greenberg M.L., Schwartz D.H., and Montefiori D.C. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 16 18 (2000) 2019-2035
5. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., and Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 3 (2004) 233-236
6. Cho M.W., Kim Y.B., Lee M.K., Gupta K.C., Ross W., Plishka R., Buckler-White A., Igarashi T., Theodore T., Byrum R., Kemp C., Montefiori D.C., and Martin M.A. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J. Virol. 75 5 (2001) 2224-2234
7. Coeffier E., Clement J.M., Cussac V., Khodaei-Boorane N., Jehanno M., Rojas M., Dridi A., Latour M., El Habib R., Barre-Sinoussi F., Hofnung M., and Leclerc C. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 19 7-8 (2000) 684-693
8. Crawford J.M., Earl P.L., Moss B., Reimann K.A., Wyand M.S., Manson K.H., Bilska M., Zhou J.T., Pauza C.D., Parren P.W., Burton D.R., Sodroski J.G., Letvin N.L., and Montefiori D.C. Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J. Virol. 73 12 (1999) 10199-10207
9. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., O'Brien W.A., Ratner L., Kappes J.C., Shaw G.M., and Hunter E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74 18 (2000) 8358-8367
10. Gallo R.C., Salahuddin S.Z., Popovic M., Shearer G.M., Kaplan M., Haynes B.F., Palker T.J., Redfield R., Oleske J., Safai B., et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224 4648 (1984) 500-503
11. Gao F., Morrison S.G., Robertson D.L., Thornton C.L., Craig S., Karlsson G., Sodroski J., Morgado M., Galvao-Castro B., von Briesen H., Beddows S., Weber J., Sharp P.M., Shaw G.M., and Hahn B.H. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J. Virol. 70 3 (1996) 1651-1667
12. Gao F., Weaver E.A., Lu Z., Li Y., Liao H.X., Ma B., Alam S.M., Scearce R.M., Sutherland L.L., Yu J.S., Decker J.M., Shaw G.M., Montefiori D.C., Korber B.T., Hahn B.H., and Haynes B.F. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J. Virol. 79 2 (2005) 1154-1163
13. Haigwood N.L., Montefiori D.C., Sutton W.F., McClure J., Watson A.J., Voss G., Hirsch V.M., Richardson B.A., Letvin N.L., Hu S.L., and Johnson P.R. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J. Virol. 78 11 (2004) 5983-5995
14. Hurwitz J.L., Slobod K.S., Lockey T.D., Wang S., Chou T.H., and Lu S. Application of the polyvalent approach to HIV-1 vaccine development. Curr. Drug Targets Infect. Disord. 5 2 (2005) 143-156
15. Kong W.P., Huang Y., Yang Z.Y., Chakrabarti B.K., Moodie Z., and Nabel G.J. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J. Virol. 77 23 (2003) 12764-12772
16. Letvin N.L., Huang Y., Chakrabarti B.K., Xu L., Seaman M.S., Beaudry K., Korioth-Schmitz B., Yu F., Rohne D., Martin K.L., Miura A., Kong W.P., Yang Z.Y., Gelman R.S., Golubeva O.G., Montefiori D.C., Mascola J.R., and Nabel G.J. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J. Virol. 78 14 (2004) 7490-7497
17. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 16 (2005) 10108-10125
18. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., Decker J.M., Li Y., Salazar M.G., Polonis V.R., Mlisana K., Karim S.A., Hong K., Greene K.M., Bilska M., Zhou J., Allen S., Chomba E., Mulenga J., Vwalika C., Gao F., Zhang M., Korber B.T., Hunter E., Hahn B.H., and Montefiori D.C. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80 23 (2006) 11776-11790
19. Liang X., Munshi S., Shendure J., Mark III G., Davies M.E., Freed D.C., Montefiori D.C., and Shiver J.W. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine 17 22 (1999) 2862-2872
20. Liao H.X., Sutherland L.L., Xia S.M., Brock M.E., Scearce R.M., Vanleeuwen S., Alam S.M., McAdams M., Weaver E.A., Camacho Z., Ma B.J., Li Y., Decker J.M., Nabel G.J., Montefiori D.C., Hahn B.H., Korber B.T., Gao F., and Haynes B.F. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353 2 (2006) 268-282
21. Long E.M., Rainwater S.M., Lavreys L., Mandaliya K., and Overbaugh J. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res. Hum. Retroviruses 18 8 (2002) 567-576
22. Mascola J.R. Defining the protective antibody response for HIV-1. Curr. Mol. Med. 3 3 (2003) 209-216
23. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., Clements M.L., Dolin R., Graham B.S., Gorse G.J., Keefer M.C., McElrath M.J., Walker M.C., Wagner K.F., McNeil J.G., McCutchan F.E., and Burke D.S. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173 2 (1996) 340-348
24. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., Petropoulos C.J., Polonis V.R., Sarzotti M., and Montefiori D.C. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79 16 (2005) 10103-10107
25. Mascola J.R., Sambor A., Beaudry K., Santra S., Welcher B., Louder M.K., Vancott T.C., Huang Y., Chakrabarti B.K., Kong W.P., Yang Z.Y., Xu L., Montefiori D.C., Nabel G.J., and Letvin N.L. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J. Virol. 79 2 (2005) 771-779
26. Mc Cann C.M., Song R.J., and Ruprecht R.M. Antibodies: can they protect against HIV infection?. Curr. Drug Targets Infect. Disord. 5 2 (2005) 95-111
27. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. In: Coligan A.M.K.J.E., Margulies D.H., Shevach E.M., Strober W., and Coico R. (Eds). Current Protocols in Immunology (2004), John Wiley and Sons, New York 12.11.1-12.11.15
28. Montefiori D.C., Robinson Jr. W.E., Schuffman S.S., and Mitchell W.M. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26 2 (1988) 231-235
29. Nara P.L., and Lin G. HIV-1: the confounding variables of virus neutralization. Curr. Drug Targets Infect. Disord. 5 2 (2005) 157-170
30. Ourmanov I., Bilska M., Hirsch V.M., and Montefiori D.C. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. J. Virol. 74 6 (2000) 2960-2965
31. Pantophlet R., and Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24 (2006) 739-769
32. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., and Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72 4 (1998) 2855-2864
33. Poss M., and Overbaugh J. Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J. Virol. 73 7 (1999) 5255-5264
34. Santra S., Barouch D.H., Korioth-Schmitz B., Lord C.I., Krivulka G.R., Yu F., Beddall M.H., Gorgone D.A., Lifton M.A., Miura A., Philippon V., Manson K., Markham P.D., Parrish J., Kuroda M.J., Schmitz J.E., Gelman R.S., Shiver J.W., Montefiori D.C., Panicali D., and Letvin N.L. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc. Natl. Acad. Sci. U.S.A. 101 30 (2004) 11088-11093
35. Scala G., Chen X., Liu W., Telles J.N., Cohen O.J., Vaccarezza M., Igarashi T., and Fauci A.S. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. J. Immunol. 162 10 (1999) 6155-6161
36. Seaman M.S., Xu L., Beaudry K., Martin K.L., Beddall M.H., Miura A., Sambor A., Chakrabarti B.K., Huang Y., Bailer R., Koup R.A., Mascola J.R., Nabel G.J., and Letvin N.L. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. 79 5 (2005) 2956-2963
37. Shaw G.M., Hahn B.H., Arya S.K., Groopman J.E., Gallo R.C., and Wong-Staal F. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science 226 4679 (1984) 1165-1171
38. Shu Y., Winfrey S., Yang Z.Y., Xu L., Rao S.S., Srivastava I., Barnett S.W., Nabel G.J., and Mascola J.R. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25 8 (2007) 1398-1408
39. Stamatatos L., Wiskerchen M., and Cheng-Mayer C. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. AIDS Res. Hum. Retroviruses 14 13 (1998) 1129-1139
40. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., and Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17 18 (2001) 1757-1765
41. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., and Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70 2 (1996) 1100-1108
42. Wang S., Pal R., Mascola J.R., Chou T.H., Mboudjeka I., Shen S., Liu Q., Whitney S., Keen T., Nair B.C., Kalyanaraman V.S., Markham P., and Lu S. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350 1 (2006) 34-47
43. Zhan X., Martin L.N., Slobod K.S., Coleclough C., Lockey T.D., Brown S.A., Stambas J., Bonsignori M., Sealy R.E., Blanchard J.L., and Hurwitz J.L. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 23 46-47 (2005) 5306-5320